CGEN · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $0.3B · 75 employees
409
SEC Filings
$2.35
Close 2026-07-31
75
Employees
Business Summary
Compugen Ltd. is a clinical-stage therapeutic discovery and development company using Unigen, its AI/ML-powered computational discovery platform, to identify novel drug targets and develop cancer immunotherapy therapeutics. Its pipeline includes COM701 (anti-PVRIG antibody), COM902 (anti-TIGIT antibody), rilvegostomig (PD-1/TIGIT bispecific, licensed to AstraZeneca), and GS-0321/COM503 (IL-18BP blocker, licensed to Gilead), all targeting solid tumors.
Look up CGEN using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on CGEN, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/CGEN (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.